The biology of hypomorphic TP53 variants and implications for clinical management.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
In individuals with classic Li Fraumeni Syndrome (LFS) due to a loss of function pathogenic germline variant in TP53, loss of p53 tumor suppressive function leads to a high risk of childhood cancers such as sarcomas, adrenal cortical carcinomas, brain tumors and leukemia. In adults with classic LFS, in addition to the classical malignancies, breast cancers and other cancers develop at earlier ages of onset compared to individuals without LFS. Increased genetic testing is identifying a higher frequency of germline TP53 variants with conflicting interpretations in clinical databases, some of which are likely hypomorphic, or of atypical penetrance. Studies of these hypomorphic TP53 variants reveal differential retention or loss of the myriad of p53 tumor suppressive functions. Many individuals with hypomorphic TP53 variants develop cancer, including both canonical and common types, though at later ages as compared to classic LFS. Therefore, further study is needed to understand the most critical tumor suppressive functions of p53 as are data-driven clinical guidelines for management of cancer risk. Herein, we review models of TP53 variant classification focusing on strategies to identify hypomorphic TP53 variants. We go on to review the biology and clinical phenotypes of TP53 hypomorphic variants that have detailed reports of their effects on p53 tumor suppressive functions. Using this framework, we propose possible modifications to the standard LFS screening protocol for individuals with hypomorphic TP53 variants that should be studied in prospective clinical trials.